Insider Selling: BeOne Medicines (NASDAQ:ONC) CFO Sells $361,805.47 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CFO Aaron Rosenberg sold 1,157 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $312.71, for a total transaction of $361,805.47. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Aaron Rosenberg also recently made the following trade(s):

• On Thursday, June 11th, Aaron Rosenberg sold 631 shares of BeOne Medicines stock. The shares were sold at an average price of $257.74, for a total value of $162,633.94.

BeOne Medicines Trading Up 5.6%

Shares of NASDAQ:ONC opened at $348.27 on Friday. The business’s 50-day moving average is $296.52 and its 200 day moving average is $308.89. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.40 and a quick ratio of 3.27. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $253.95 and a 1 year high of $385.22. The firm has a market capitalization of $38.21 billion, a P/E ratio of 61.32 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $2.05 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.65. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%.The business had revenue of $1.71 billion during the quarter, compared to the consensus estimate of $1.66 billion. On average, research analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 6.26 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on ONC shares. Royal Bank Of Canada dropped their target price on shares of BeOne Medicines from $451.00 to $450.00 and set an “outperform” rating on the stock in a research report on Thursday. Citigroup reaffirmed an “outperform” rating on shares of BeOne Medicines in a report on Thursday. Zacks Research downgraded shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 3rd. JPMorgan Chase & Co. upped their target price on BeOne Medicines from $415.00 to $425.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Finally, Wells Fargo & Company started coverage on BeOne Medicines in a research note on Monday, May 4th. They issued an “overweight” rating and a $400.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, BeOne Medicines has a consensus rating of “Moderate Buy” and an average target price of $400.00.

Institutional Trading of BeOne Medicines

Several institutional investors and hedge funds have recently bought and sold shares of the business. Generali Investments Management Co LLC purchased a new stake in shares of BeOne Medicines in the 2nd quarter valued at $2,280,000. Charles Schwab Trust Co purchased a new position in shares of BeOne Medicines during the second quarter worth $855,000. Steadtrust LLC raised its holdings in shares of BeOne Medicines by 3.7% during the second quarter. Steadtrust LLC now owns 1,400 shares of the company’s stock worth $399,000 after purchasing an additional 50 shares during the last quarter. Empowered Funds LLC acquired a new position in BeOne Medicines during the first quarter valued at $201,000. Finally, Bank of America Corp DE lifted its position in BeOne Medicines by 7.0% during the first quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock valued at $120,354,000 after purchasing an additional 26,441 shares during the period. 48.55% of the stock is currently owned by institutional investors and hedge funds.

More BeOne Medicines News

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Strong Q2 performance: BeOne reported adjusted earnings of $2.05 per share, topping the $1.40 consensus estimate, while revenue reached $1.71 billion versus expectations of $1.66 billion. The earnings beat reinforces confidence in the company’s oncology portfolio and profitability. BeOne Medicines Q2 earnings report
• Positive Sentiment: 2026 outlook raised: Management increased its full-year revenue forecast to approximately $6.6 billion-$6.8 billion, above Wall Street’s prior estimate of $6.5 billion, citing a 30% quarterly revenue surge. BeOne Medicines raises 2026 outlook
• Positive Sentiment: Analyst targets moved higher: TD Cowen raised its target to $454 and assigned a Buy rating; Guggenheim increased its target to $430, Truist lifted its target to $418, and Citizens JMP raised its target to $405. RBC made a modest reduction to $450 but retained an Outperform rating. Collectively, the updates indicate substantial implied upside from recent trading levels. Analyst price-target updates
• Positive Sentiment: Institutional buying: Bank of America, Man Group, BNP Paribas and other institutions recently established or expanded positions, suggesting continued professional-investor interest in ONC.
• Neutral Sentiment: Insider sale was tax-related: CFO Aaron Rosenberg sold 1,157 shares valued at about $362,000 to cover tax withholding from vested equity awards. The transaction is therefore a limited bearish signal. SEC insider transaction filing
• Negative Sentiment: Valuation risk: With a high earnings multiple and the stock trading below its 52-week high, investors may require continued rapid growth and execution to justify the current valuation.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.